Literature DB >> 21421722

Evaluation of chemotherapy response in VX2 rabbit lung cancer with 18F-labeled C2A domain of synaptotagmin I.

Feng Wang1, Wei Fang, Ming-Rong Zhang, Ming Zhao, Biao Liu, Zizheng Wang, Zichun Hua, Min Yang, Katsushi Kumata, Akiko Hatori, Tomoteru Yamasaki, Kazuhiko Yanamoto, Kazutoshi Suzuki.   

Abstract

UNLABELLED: The C2A domain of synaptotagmin I can target apoptotic cells by binding to exposed anionic phospholipids. The goal of this study was to synthesize and develop (18)F-labeled C2A-glutathione-S-transferase (GST) as a molecular imaging probe for the detection of apoptosis and to assess the response of paclitaxel chemotherapy in VX2 rabbit lung cancer.
METHODS: (18)F-C2A-GST was prepared by labeling C2A-GST with N-succinimidyl 4-(18)F-fluorobenzoate ((18)F-SFB). (18)F-C2A-GST was confirmed by high-performance liquid chromatography and sodium dodecyl sulfate polyacrylamide gel electrophoresis. The binding of (18)F-C2A-GST toward apoptosis was validated in vitro using camptothecin-induced Jurkat cells. Biodistribution of (18)F-C2A-GST was determined in mice by a dissection method and small-animal PET. Single-dose paclitaxel was used to induce apoptosis in rabbits bearing VX2 tumors (n = 6), and 2 VX2 rabbits without treatment served as control. (18)F-C2A-GST PET was performed before and at 72 h after therapy, and (18)F-FDG PET/CT was also performed before treatment. To confirm the presence of apoptosis, tumor tissue was analyzed and activated caspase-3 was measured.
RESULTS: (18)F-C2A-GST was obtained with more than 95% radiochemical purity and was stable for 4 h after formulation. (18)F-C2A-GST bound apoptotic cells specifically. Biodistribution in mice showed that (18)F-C2A-GST mainly excreted from the kidneys and rapidly cleared from blood and nonspecific organs. High focal uptake of (18)F-C2A-GST in the tumor area was determined after therapy, whereas no significant uptake before therapy was found in the tumor with (18)F-FDG-avid foci. The maximum standardized uptake value after therapy was 0.47 ± 0.28, significantly higher than that in the control (0.009 ± 0.001; P < 0.001). The apoptotic index was 79.81% ± 8.73% in the therapy group, significantly higher than that in the control (5.03% ± 0.81%; P < 0.001). Activated caspase-3 after paclitaxel treatment increased to 69.55% ± 16.27% and was significantly higher than that in the control (12.26% ± 5.39%; P < 0.001).
CONCLUSION: (18)F-C2A-GST was easily synthesized by conjugation with (18)F-SFB and manifested a favorable biodistribution. Our results demonstrated the feasibility of (18)F-C2A-GST for the early detection of apoptosis after chemotherapy in a VX2 lung cancer model that could imitate the human lung cancer initiation, development, and progress.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21421722      PMCID: PMC3866918          DOI: 10.2967/jnumed.110.081588

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  28 in total

1.  Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent.

Authors:  M Zhao; D A Beauregard; L Loizou; B Davletov; K M Brindle
Journal:  Nat Med       Date:  2001-11       Impact factor: 53.440

Review 2.  Apoptosis-detecting radioligands: current state of the art and future perspectives.

Authors:  Christophe M M Lahorte; Jean-Luc Vanderheyden; Neil Steinmetz; Christophe Van de Wiele; Rudi A Dierckx; Guido Slegers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-12       Impact factor: 9.236

3.  Near-infrared fluorescent imaging of tumor apoptosis.

Authors:  Alexander Petrovsky; Eyk Schellenberger; Lee Josephson; Ralph Weissleder; Alexei Bogdanov
Journal:  Cancer Res       Date:  2003-04-15       Impact factor: 12.701

4.  Apoptosis may be an early event of progestin therapy for endometrial hyperplasia.

Authors:  C A Amezcua; J J Lu; J C Felix; F Z Stanczyk; W Zheng
Journal:  Gynecol Oncol       Date:  2000-11       Impact factor: 5.482

5.  Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis.

Authors:  Tarik Belhocine; Neil Steinmetz; Roland Hustinx; Pierre Bartsch; Guy Jerusalem; Laurence Seidel; Pierre Rigo; Allan Green
Journal:  Clin Cancer Res       Date:  2002-09       Impact factor: 12.531

Review 6.  Transbilayer phospholipid movement and the clearance of apoptotic cells.

Authors:  Patrick Williamson; Robert A Schlegel
Journal:  Biochim Biophys Acta       Date:  2002-12-30

7.  Synthesis and evaluation of a 18F-labelled recombinant annexin-V derivative, for identification and quantification of apoptotic cells with PET.

Authors:  S Zijlstra; J Gunawan; W Burchert
Journal:  Appl Radiat Isot       Date:  2003-02       Impact factor: 1.513

8.  18F-labelled annexin V: a PET tracer for apoptosis imaging.

Authors:  Yoshihiro Murakami; Hiroyuki Takamatsu; Junichi Taki; Mitsuyoshi Tatsumi; Akihiro Noda; Rikiya Ichise; Jonathan F Tait; Shintaro Nishimura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12-10       Impact factor: 9.236

Review 9.  In vivo detection of apoptosis.

Authors:  Francis G Blankenberg
Journal:  J Nucl Med       Date:  2008-06       Impact factor: 10.057

10.  Visualization of antitumor treatment by means of fluorescence molecular tomography with an annexin V-Cy5.5 conjugate.

Authors:  Vasilis Ntziachristos; Eyk A Schellenberger; Jorge Ripoll; Doreen Yessayan; Edward Graves; Alexei Bogdanov; Lee Josephson; Ralph Weissleder
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-10       Impact factor: 11.205

View more
  12 in total

Review 1.  Radiopharmaceuticals as probes to characterize tumour tissue.

Authors:  Israt S Alam; Mubarik A Arshad; Quang-Dé Nguyen; Eric O Aboagye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-03       Impact factor: 9.236

Review 2.  New frontiers in the design and synthesis of imaging probes for PET oncology: current challenges and future directions.

Authors:  Graham Smith; Laurence Carroll; Eric O Aboagye
Journal:  Mol Imaging Biol       Date:  2012-12       Impact factor: 3.488

Review 3.  Biomarkers and molecular probes for cell death imaging and targeted therapeutics.

Authors:  Bryan A Smith; Bradley D Smith
Journal:  Bioconjug Chem       Date:  2012-09-26       Impact factor: 4.774

4.  Transbilayer phospholipids molecular imaging.

Authors:  Tarik Z Belhocine; Frank S Prato
Journal:  EJNMMI Res       Date:  2011-08-22       Impact factor: 3.138

Review 5.  Molecular imaging of apoptosis: from micro to macro.

Authors:  Wenbin Zeng; Xiaobo Wang; Pengfei Xu; Gang Liu; Henry S Eden; Xiaoyuan Chen
Journal:  Theranostics       Date:  2015-02-20       Impact factor: 11.556

6.  Characterization of [(99m)Tc]Duramycin as a SPECT Imaging Agent for Early Assessment of Tumor Apoptosis.

Authors:  Filipe Elvas; Christel Vangestel; Sara Rapic; Jeroen Verhaeghe; Brian Gray; Koon Pak; Sigrid Stroobants; Steven Staelens; Leonie Wyffels
Journal:  Mol Imaging Biol       Date:  2015-12       Impact factor: 3.488

Review 7.  Avenues to molecular imaging of dying cells: Focus on cancer.

Authors:  Anna A Rybczynska; Hendrikus H Boersma; Steven de Jong; Jourik A Gietema; Walter Noordzij; Rudi A J O Dierckx; Philip H Elsinga; Aren van Waarde
Journal:  Med Res Rev       Date:  2018-03-12       Impact factor: 12.944

8.  Highly specific PET imaging of prostate tumors in mice with an iodine-124-labeled antibody fragment that targets phosphatidylserine.

Authors:  Jason H Stafford; Guiyang Hao; Anne M Best; Xiankai Sun; Philip E Thorpe
Journal:  PLoS One       Date:  2013-12-19       Impact factor: 3.240

9.  Monitoring Apoptosis of Breast Cancer Xenograft After Paclitaxel Treatment With 99mTc-Labeled Duramycin SPECT/CT.

Authors:  Rui Luo; Lei Niu; Fan Qiu; Wei Fang; Tong Fu; Ming Zhao; Ying-Jian Zhang; Zi-Chun Hua; Xiao-Feng Li; Feng Wang
Journal:  Mol Imaging       Date:  2016-01-29       Impact factor: 4.488

10.  Clinical translation of [18F]ICMT-11 for measuring chemotherapy-induced caspase 3/7 activation in breast and lung cancer.

Authors:  S R Dubash; S Merchant; K Heinzmann; F Mauri; I Lavdas; M Inglese; K Kozlowski; N Rama; N Masrour; J F Steel; A Thornton; A K Lim; C Lewanski; S Cleator; R C Coombes; Laura Kenny; Eric O Aboagye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-27       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.